German Government Plans Higher Out-of-Pocket Payments for Medications

The German federal government is preparing to implement substantial changes to the statutory health insurance system (GKV), aiming to generate savings as part of a new cost-cutting law. A key element of these reforms involves raising the mandatory co-payments for prescription medicines and hospital treatments, which will directly affect insured individuals across the country.

Under the proposed measures, the minimum personal contribution for prescription drugs will increase from the current range of 5 to 10 euros, shifting to a new bracket of at least 7.50 euros and up to 15 euros per medication. This adjustment is intended to contribute approximately 1.9 billion euros in overall savings for the health system, according to government projections. In addition, pharmacies will face an increased charge--known as the 'Kassenabschlag'--with each prescription they process, targeting an additional 200 million euros in savings from this sector alone.

For insured patients, the law stipulates that they must pay 10 percent of the retail price for prescribed medicines. However, the revised regulation will see the co-payment thresholds rise, with the minimum and maximum patient contributions both increasing. These changes are designed to ensure the continued financial stability of the health insurance system amid rising healthcare costs.

To assist the public in understanding these new rules, informational materials, such as flyers, have been distributed in pharmacies. These explain the calculation of co-payments and emphasize that pharmacies do not retain the co-payment fees; instead, they collect these amounts on behalf of the health insurance funds. The materials also highlight potential ways for patients to reduce their out-of-pocket expenses. For example, individuals are encouraged to ask their pharmacists if a medication exempt from co-payments is available. Furthermore, those who face particularly high medical expenses--such as patients with chronic illnesses--may be eligible for exemption from co-payments, depending on their income level. Patients are advised to consult directly with their health insurance provider regarding qualification for such exemptions.

The law maintains the maximum annual co-payment limit, which remains at 2 percent of gross annual income for most insured individuals. For patients with chronic conditions, this limit is set at 1 percent of gross income. This cap is intended to protect individuals from excessive financial burdens due to ongoing healthcare needs.

Another significant aspect of the reform is the planned annual adjustment of co-payment amounts. According to the draft legislation, co-payments will be recalibrated every year based on the average rate of change in healthcare costs, as specified by Section 71, Paragraph 3 of the German Social Code. The Federal Ministry of Health will announce these new amounts in the official federal register by September 15 each year. This mechanism is intended to ensure that patient contributions remain aligned with broader economic trends in healthcare expenditure.

Pharmacists' associations have expressed concern about the increased administrative workload, as pharmacies continue to act as collection points for the insurance funds. Some groups have called for the government to relieve pharmacies of this responsibility, citing the growing complexity and associated costs.

These reforms, which form part of the broader GKV cost-containment package, also include measures affecting clinics, outpatient practices, and pharmaceutical manufacturers. For pharmacies, the increase in the mandatory deduction per prescription--from 1.77 euros to 2.07 euros--is scheduled to take effect at the turn of the year, as outlined in the updated legislative proposal.

Overall, the planned changes are part of a comprehensive strategy to safeguard the financial viability of Germany's statutory health insurance system, while balancing the interests of patients, healthcare providers, and insurers.